Conditions: Chronic Obstructive Pulmonary Disease
Keywords: COPD, chronic obstructive pulmonary disease; Safety, Pharmacokinetics
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 11
Healthy volunteers: no

Brief summary:
The primary objective of the study is to assess the safety and tolerability of multiple infusions of andecaliximab (formerly GS-5745) in participants with chronic obstructive pulmonary disease (COPD) as assessed by adverse events (AEs) and laboratory abnormalities.

Detailed description:

Arms:
arm 1: Participants will receive andecaliximab every 2 weeks for a total of 3 infusions. arm 2: Participants will receive placebo to match andecaliximab every 2 weeks for a total of 3 infusions.

Interventions: intervention 1: Andecaliximab intervention 2: Placebo to match Andecaliximab
Intervention descriptions: intervention 1: 400 mg andecaliximab administered intravenously intervention 2: Placebo to match andecaliximab administered intravenously

Protocol document: